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Abstract 
Background: Matrix-metalloproteinases 9 (MMP-9) belongs to the class of matrix metalloproteinases whose main 
function is to degrade and remodel the extracellular matrix (ECM). MMP-9 has been shown to be an integral part of 
many diseases where modulation of the ECM is a key step such as cancer, osteoporosis and fibrosis. MMP-9 is secreted 
as a latent pro-enzyme that requires activation in the extracellular space. Therefore, identifying physiological and 
molecular contexts, which can activate MMP-9 is important.
Results: Acidification of osteoclast-conditioned media to pH 5 resulted in a fragment with a size corresponding to 
active MMP-9. Also, treatment of recombinant proMMP-9 with recombinant cathepsin K (CTSK) at pH 5 yielded a frag-
ment that corresponded to the molecular weight of active MMP-9, and showed MMP-9 activity. This activation was 
abrogated in the presence of CTSK inhibitor indicating that CTSK was responsible for the activation of pro-MMP-9. 
Knocking down CTSK in MDA-MB-231 cells also diminished MMP-9 activity compared to wild type control.
Conclusions: Here we provide the first evidence that CTSK can cleave and activate MMP-9 in acidic environments 
such as seen in tumors and during bone resorption. This finding provides a key link between CTSK expression in 
tumors and bone and ECM remodeling, through MMP-9 activation. This novel mechanism to activate MMP-9 through 
extracellular physiological changes elucidated in this study reveals a protease-signaling network involving CTSK and 
MMP-9 and provides the impetus to explore ECM proteases as physiological markers and pharmacological targets.
Keywords: Enzyme activation, MMP-9 activation, CTSK, Bone resorption, Cancer therapy
© 2015 Christensen and Shastri. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Matrix metalloproteinase-9 (MMP-9) is a zinc-depend-
ent endopeptidase that participates in a variety of physi-
ological and biochemical processes. In tumor biology, 
MMP-9 plays an important role in tumor progression 
and it has been shown that MMP-9 increases angiogene-
sis [1], cancer cell migration [2] and metastasis [3]. In the 
tumor microenvironment infiltrating cells, such as bone 
marrow cells [1], tumor associated macrophages [4, 5] 
and neutrophils [6] have been shown to be a rich source 
of MMP-9 and tumor cells themselves express higher lev-
els of MMP-9 compared to healthy tissue [7]. Also, it has 
been shown that cancer cells can induce expression of 
proteolytic enzymes such as MMP-2, MMP-9 and uroki-
nase in adjacent fibroblasts through paracrine signalling 
[8–10]. MMP-9 has also been shown to be important for 
bone development and repair. MMP-9 knockout mice 
exhibit altered growth plate vascularization and ossifica-
tion during development and delayed repair of experi-
mental induced bone fractures [11, 12].
MMP-9 is secreted as an inactive enzyme (proMMP-9) 
with a molecular weight of 92  kDa. A cysteine in the 
N-terminal pro-domain binds to the zinc atom in the 
active site thus maintaining latency [13]. Activation of 
MMP-9 requires a disruption of the cysteine interac-
tion with the zinc atom thus exposing the catalytic site 
[13]. The most studied mechanism of MMP-9 activa-
tion is enzyme proteolysis of the pro-domain. Activa-
tors of MMP-9 include MMP-2 [14, 15], MMP-3 [14, 
16], MMP-7 [17], MMP-10 [18], MMP-13 [19], cath-
epsin G [20] and urokinase/plasmin [21, 22]. Among 
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these MMP-3 is considered the most potent activator of 
MMP-9 [23]. Activation of pro-MMP-9 by the aforemen-
tioned activators results in active MMP-9, which has a 
molecular weight in the neighborhood of 82  kDa. Post-
activation processing of MMP-9 can lead to the removal 
of the C-terminal hemopexin-like domain (65  kDa spe-
cies) or a direct cleavage of the active site leading to an 
inactive species (50–60 kDa) [24].
Lysosomal cysteine cathepsin (LCC) is a subgroup of 
the family of cathepsin proteases that requires an acidic 
environment for optimal activation, and is found mainly 
in the acidic lysosomes where they participate in pro-
tein turnover and degradation of internalized ECM [25]. 
CTSK is a member of the LCC sub group, but as opposed 
to other LCC, CTSK is mainly secreted into the extra-
cellular space where it can degrade fibrillar collagen as 
found in bone and cartilage [26]. High CTSK expres-
sion has been found in osteoclasts (Ocs) and synovial 
fibroblasts, where it is responsible for the degradation 
of bone and articular cartilage [27, 28], respectively, and 
in cells associated with breast and prostate cancer meta-
static lesions in bone [29–31]. Like CTSK, MMP-9 is also 
highly expressed in Ocs, and synovial fibroblasts where 
it contributes to degradation of the ECM [32, 33]. In 
bone metastasis MMP-9 is associated with loss of bone 
matrix and participates in catabolism of bone [34]. Due 
to the restricted expression profile of CTSK compared 
to other LCCs, and its overlap with the expression of 
MMP-9 we hypothesized that CTSK and MMP-9 might 
be involved in a protease-signaling network. We investi-
gated this premise in this study and present evidence that 
CTSK can cleave and activate proMMP-9 under acidic 
conditions.
Results and discussion
Osteoclast‑derived CTSK can process proMMP‑9
Epidemiological studies show that incidence of bone 
metastasis is reduced in both early and late-stage breast 
cancer patients receiving bisphosphonate, suggesting a 
possible link between bone turnover and metastasis to 
the bone [35]. It is well established that tumor environ-
ments and breast and prostate cancer metastasis lesions 
in bone show high expression of CTSK. Elevated levels of 
MMP-9 have also been linked to breast cancer and tumor 
invasion [2]. Interestingly, CTSK expression has also been 
reported in the population of breast and prostate cancer 
cells that metastasize to bone [29–31]. However, why the 
acquisition of a CTSK expressing phenotype might be 
important for cancer cells still remains unanswered.
Since a key pathological trait of osteoporosis is 
increased osteoclastic activity we examined the expres-
sion levels of CTSK and MMP-9 in Ocs derived from 
human monocytes differentiated in the presence of 
RANKL and observed that in addition to morphologi-
cal characteristics such as TRAP positive giant multinu-
cleated cells, upregulation of CTSK and ACP5 mRNA 
(Fig.  1a, b) monocyte-derived Oc also express MMP-9 
mRNA (Fig. 1b). Additionally, the Oc secretome showed 
secretion of active CTSK (Fig.  1c) and proMMP-9 
(Fig.  1d) indicating that both CTSK and proMMP-9 
are available in the extracellular milieu. We then posed 
the question, if proMMP-9 was a substrate for CTSK 
secreted by Ocs. To test this, conditioned media (CM) 
from Ocs was acidified to pH 5, with and without a CTSK 
inhibitor, and the fate of proMMP-9 was assessed by 
gelatin zymography. Bands in zymography correspond-
ing to a calculated molecular weight of 99 and 87  kDa 
were observed, and this corresponded well with theo-
retical size of pro- and active- MMP-9 which is 92 and 
82 kDa, respectively (Fig. 1e). Addition of CTSK inhibi-
tor resulted in the loss of the zymography band at 87 
KDa, indicating a potential role for CTSK in processing 
proMMP-9. Furthermore, the osteoclasts conditioned 
media was assayed for MMP-3 and MMP-3 was not 
detected (Additional file 1). This further strengthens the 
conclusion that CTSK is an activator of MMP-9.
rhCTSK enzymatically activates rhproMMP‑9
To further confirm the above findings and to exclude 
the role of other secreted lysosomal cysteine proteases 
active under acidified conditions in the processing of 
proMMP-9, we used recombinant human proMMP-9 
(rhproMMP-9) and CTSK (rhCTSK) and we observed 
that rhCTSK could also cleave rhproMMP-9 at pH 5 and 
yielded the same molecular weight fragments of MMP-9 
as was observed with Oc CM (Fig.  2a, b). While, some 
cleavage of rhproMMP-9 by rhCTSK was also observed 
at physiological pH, it was evident that this process was 
most efficient at pH 5. A time course study revealed that 
the cleavage of rhproMMP-9 showed time dependence 
with an initial rapid increase in cleavage of rhproMMP-9 
reaching a plateau after 1 h (Fig. 2c, d).
rhCTSK cleavage of rhproMMP‑9 results in enzymatically 
active rhMMP‑9
Since the active site of MMP-9 is between the 107–444 
AA residues, it is plausible that the enzymatic cleav-
age of rhproMMP-9 by rhCTSK at either or both the 
C- or N-terminus could give rise to similar molecu-
lar weight fragments that would still be detectable by 
zymography, as the catalytic domain would be retained 
in both instances. In order to gain insight into the site 
of action of rhCTSK within rhproMMP-9, we incu-
bated rhproMMP-9 sequentially with rhCTSK followed 
by 4-aminophenylmercuric acetate (APMA) and deter-
mined the molecular weight of the fragments. Since 
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APMA is known to promote the autocatalytic cleavage of 
rhproMMP-9 at the N-terminus, if rhCTSK cleaves at the 
N-terminal (pro-domain) [24], then a single 82 kDa frag-
ment should be obtained. On the other hand if rhCTSK 
cleaves at the C-terminus (hemoplexin domain) then sub-
sequent incubation with APMA would result in a further 
removal of a 10 kDa fragment, resulting in an additional 
72  kDa fragment. However, treating rhproMMP-9 with 
rhCTSK and APMA gave rise to a rhMMP-9 fragment 
with a molecular weight of 82  kDa (Fig.  2e), providing 
evidence that in all likelihood APMA and CTSK act in 
the same vicinity within the prodomain of MMP-9. The 
presence of lower molecular weight fragment in the pres-
ence of APMA can be attributed to the autocatalytic 
cleavage of rhMMP-9 in presence of APMA, which is 
known [24].
To examine if the cleavage of rhproMMP-9 by 
rhCTSK yielded the enzymatically active rhMMP-9, 
Fig. 1 Characterization of human monocyte-derived osteoclasts secreted protease activity. a Bright field image of monocytes and differenti-
ated osteoclasts stained for TRAP. Scale bar 10 µm. b qRT-PCR of freshly isolated CD14+ monocytes and differentiated osteoclasts. Values were first 
normalized to RRN18S and then to the gene expression levels in monocytes. Data is presented as the mean ± SD, n = 3. c CM from freshly isolated 
CD14+ monocytes and differentiated osteoclasts were analyzed for the presence of active CTSK. Data is presented as the mean ± SD, n = 3. d CM 
from Ocs were subjected to Western blot analysis and probed with an antibody against proMMP-9. 20 ng of rhproMMP-9 was used as a positive 
control. e Gelatin zymography of Oc CM. The pH of the CMs was maintained at 7.4 or lowered to 5.0 and incubated for 1 h at 37°C with or without a 
CTSK inhibitor. Afterwards, the samples were analyzed by gelatin zymography. *P < 0.05 and ***P < 0.005.
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we pre-treated rhproMMP-9 with rhCTSK and fol-
lowed rhMMP-9 activity using a fluorescence assay. A 
marked increase in fluorescence intensity was observed 
in the conditions that involved acidification in presence 
of rhCTSK. To verify that this increase was indeed due 
to the action of rhCTSK on rhproMMP-9, the experi-
ment was repeated in presence of a CTSK inhibitor. A 
100-fold decrease in rhMMP-9 activity was observed 
suggesting that rhCTSK cleaves the rhproMMP-9 lead-
ing to its activation and provides circumstantial evi-
dence for a protease-signaling network involving CTSK 
and pro-MMP-9 in vitro (Fig. 2f ). This important find-
ing need to be further investigated in  vivo in animal 
models.
Fig. 2 rhCTSK can cleave and activate rhproMMP-9 at acidic pH. a rhproMMP-9 (5.0 ng) was incubated with rhCTSK (0.5 ng) at pH 5.0 for the dura-
tion indicated, and then analyzed via gelatin zymography. b Quantification of active MMP-9 using the zymography data shown in a. Y-axis is the 
ratio between active- and proMMP-9, measured from the relative light intensity. Data is presented as mean ± SD, n = 3. c Zymograph of solutions 
of rhproMMP-9 (5.0 ng) incubated for 1 h, at 37°C with or without rhCTSK (0.5 ng) at pH 7.5 or pH 5.0.  d Quantification of zymography bands 
shown in c. Y-axis is the ratio between active- and proMMP-9, measured from the relative light intensity of the bands normalized to the control 
condition without rhCTSK. Data is presented as the mean ± SD, n = 8. e rhproMMP-9 (5.0 ng) was first incubated for 1 h at 37°C at pH 5.0 with or 
without rhCTSK (5.0 ng), and then pH was adjusted to 8.0 and incubated for an additional 2 h at 37°C with or without APMA (final concentration 
1.5 mM), and then analyzed via gelatin zymography. f Quantification of MMP-9 activity using a fluorescently quenched substrate for MMP-9 (Mca-
RPPGFSAFK(Dnp)). Data is presented as the mean ± SD, n = 3. *P < 0.05 and **P < 0.01.
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Tumor derived CTSK activates proMMP‑9
MMP-9 expression is thought to be a key in promoting 
pro-tumorigenic and pro-metastatic signaling cascades 
within the tumor environment [36]. Overexpression of 
MMP-9 is often found within tumors, where it can con-
tribute to tumor progression through angiogenesis and 
increased migration of tumor cells [1, 2]. So it is possible, 
that CTSK within tumor environments and in bone met-
astatic lesions has an additional role of activating MMP-
9. To test whether endogenous expression of CTSK could 
indeed activate tumor derived MMP-9, we examined 
MMP-9 activity following knockdown of CTSK mRNA 
using shRNA in the metastatic breast cancer cell line 
MDA-MB-231. The knockdown resulted in a significant 
reduction of CTSK mRNA expression level, which was 
accompanied by reduction in both cytosolic and secreted 
CTSK activity (Fig. 3a–c). In this scenario, lowering the 
pH of CM collected from MDA-MB-231 WT and MDA-
MB-231 CTSK-KD yielded a significantly lower activity 
of MMP-9 in the CM collected from the cells depleted 
of CTSK (Fig.  3d). However, knockdown of CTSK did 
not alter MMP-9 mRNA and proteins levels (Fig. 3e, f ), 
thus demonstrating that MDA-MB-231 secretes CTSK 
that it is capable of activating endogenously secreted 
proMMP-9. This is a significant finding, which if dem-
onstrated in  vivo could imply that cancer cells could 
modulate their microenvironment through CTSK-
MMP-9 interplay. However, whether CTSK activation of 
proMMP-9 can regulate tumor progression needs to be 
extensively investigated in appropriate animal models 
before drawing broad and general conclusions.
Conclusions
The results of this study provide the first evidence that 
CTSK can cleave proMMP-9 under acidic conditions. 
This finding is of significance as it is well established that 
MMP-9 promotes angiogenesis and cell migration [1, 2]. 
Since the tumor environment is inherently acidic due to 
high rate of glycolysis (Warburg Effect) the necessary 
trigger for secreted CTSK to act on latent proMMP-9 is 
ever present. Our finding that proMMP-9 and CTSK are 
secreted by both OCs and the metastatic breast cancer 
cell line MDA-MB-231 allude to a potential paradigm 
where the activation of proMMP-9 can occur through 
crosstalk between OCs resorptive pits and arriving breast 
cancer cells. The findings of this study provide further 
credence to this strategy of targeting CTSK activity to 
limit bone metastasis and also provide a framework for 
exploring more specific inhibitors of CTSK that interfer-
ence with biding and activation of pro-MMP-9. However, 
the ability CTSK-proMMP-9 nexus to influence and alter 
tumor behavior needs to be verified in vivo.
Methods
Cell lines
The epithelial cell line MDA-MB-231 and HEK293 was 
cultured in Dulbecco’s modified Eagle essential medium 
(DMEM) Glutamax containing 10% FCS and cultured 
at 37°C and 5% CO2. MDA-MB-231 and HEK293 was 
provided by the Centre for Biological Signalling Studies 
(BIOSS) and were genotyped and verified at Labor für 
DNA Analytik (Freiburg, Germany).
Lentiviral production and transduction
Lentiviral particles containing shRNA constructs 
(shCTSK V2LHS-92790-C5 and control RHS4346, Fisher 
Scientific, Germany) were produced in HEK293 cells, by 
co-transfecting lentiviral vector and packaging vectors 
using polyethylenimine (Mw 25.000, Sigma, Germany) as 
the transfection reagent. For transfection, 30 µg of DNA 
(4:3:1 of transfer vector, packaging coding vector (pCMV-
dR8.74) and envelope coding vector (pMD2.G)) was 
diluted in 250 µL Opti-MEM (Invitrogen, Germany) and 
11.25  µL of polyethylenimine (1  mg/mL) was added to 
the solution and the resulting mixture was incubated for 
1 h at room temperature prior to adding to HEK293 cells. 
The medium was changed after 16 h to DMEM with 10% 
FCS and 40 and 64 h after transfection the viral superna-
tants were collected and filtered through a sterile 0.45 µm 
syringe filter (Millipore, Germany). Viral particles were 
added to target cells (MDA-MB-231) supplemented with 
5 µg/mL polybrene (Sigma, Germany). 3 days after trans-
duction, infected cells were selected by adding 5 µg/mL 
puromycin (Sigma, Germany) to the culture medium.
Monocyte isolation and differentiation
Buffy coats were procured from donated blood as per 
the guidelines of the University Clinic at the University 
Freiburg. PMBC were isolated from buffy coats by Ficoll-
Paque according to manufactures protocol (VWR, Ger-
many), and CD14+ monocytes were isolated using CD14 
magnetically labeled micro beads as per the manufac-
tures protocol (Miltenyi Biotec, Germany). Monocytes 
were seeded at a concentration of 1.5 × 106 cell/cm2 and 
cultured for 4 days in alpha-MEM (Invitrogen, Germany) 
basic medium (HEPES, sodium pyruvate, penicillin–
streptomycin-glutamine, 10% FCS) supplemented with 
25 ng/mL rhM-CSF (RnD Systems, Germany) after which 
the media was supplemented with 50  ng/mL rhRANK-
L (RnD Systems, Germany). Media was changed every 
4 days, osteoclast formation was observed after 4 weeks 
of culture. Osteoclasts were stained with tartrate-resist-
ant acid phosphatase (TRAP) staining kit (Sigma, Ger-
many) according to manufactures protocol. The nuclei 
were stained with DAPI.
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Quantitative real‑time PCR
Total RNA was extracted using RNeasy Mini Kit (Qiagen). 
Reverse transcription of mRNA to cDNA was done using 
QuantiTect reverse transcription kit (Qiagen). Quantitative 
real-time PCR was performed using Rotor-Gene SYBR-
Green PCR assay (Qiagen, Germany) on a Rotor-Gene Q 
Fig. 3 Endogenous CTSK can active endogenous MMP-9 in triple negative metastatic breast cancer cells MDA-MB-231. a Immunoblot of CTSK 
from total cell lysates of MDA-MB-231 cells transduced with scrambled mirRNA sequence (WT) or a mirRNA sequence targeting CTSK (CTSK KD). 
GAPDH band was used as the loading control. b qRT-PCR of CTSK mRNA levels in MDA-MB-231 WT and MDA-MB-231 CTSK-KD. CTSK mRNA levels 
were normalized to RRS18 N and the data is represented as the mean ± SD, n = 3. c CTSK activity was measured in conditioned media (pH 5.0) 
and total cell lysate (pH 5.0) from MDA-MB-231 WT and MDA-MB-231 CTSK-KD. Data is represented as the mean ± SD, n = 5. d MMP-9 activity as 
measured in the conditioned media from MDA-MB-231 WT and MDA-MB-231 CTSK-KD. Media was acidified to pH 5.5 or pH 7.4 and incubated for 
1 h at 37°C, afterwards the pH was adjusted to 7.4 and MMP-9 activity was measured using a fluorescently quenched substrate for MMP-9 (Mca-
RPPGFSAFK(Dnp)). Data is represented as the mean ± SD, n = 5. e qRT-PCR of MMP-9 mRNA levels in MDA-MB-231 WT and MDA-MB-231 CTSK-KD. 
MMP-9 mRNA levels were normalized to RRS18 N and data is represented as mean ± SD, n = 3. f Immunoblot of proMMP-9 from total cell lysates of 
MDA-MB-231 WT and MDA-MB-231 CTSK-KD. GAPDH band was used as loading control.*P < 0.05, **P < 0.01 and ***P < 0.005.
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machine (Qiagen, Germany), with the following thermal 
cycling conditions: 2 min at 50°C, 10 min at 95°C, followed 
by 40 cycles at 95°C for 15 s and 60°C for 1 min. All biolog-
ical samples were measured in triplicates, and the resulting 
data were normalized to RRS18 N. The following qRT-PCR 
primers were used ACP5_F: AATGTCTCTGCCCAGA 
TTGC, ACP5_R: GAAGTGCAGGCGGTAGAAAG, 
CTSK_F: CCGCAGTAATGACACCCTTT, CTSK_R: 
GCACCCACAGAGCTAAAAGC, MMP-9_F: CATC 
GTCATCCAGTTTGGTG, MMP-9_R: AGGGACCACA 
ACTCGTCATC, RRS18N_F: CGGCTACCACATCCAAG 
GAA and RRS18N_R: GCTGGAATTACCGCGGCT.
Western blot
For immunoblotting, cells were lysed in Laemmli buffer, 
and protein concentration was determined using Pierce 
BCA protein assay kit (Life Technologies). 20 μg of pro-
tein was loaded per sample and resolved on a 8% (wt/
vol) polyacrylamide–SDS gel and transferred onto nitro-
cellulose membranes, which were immediately blocked 
with 3% (w/v) BSA for 1 h. Membranes were then probed 
with an antibody against CTSK (Millipore, MAB3324) or 
proMMP-9 (R&D systems, MAB9111). GAPDH (Santa 
Cruz Biotechnology, SC-25778) was used as a loading 
control. Blots were developed using peroxidase-conju-
gated secondary antibodies and chemiluminescence sys-
tem (Thermo Scientific).
Zymography
Electrophoresis was performed with 10% polyacryla-
mide/sodium dodecyl sulfate gels containing 1  mg/ml 
of gelatin (Sigma, Germany). Sodium dodecyl sulfate 
was removed by washing in 2.5% Triton X-100 for 1  h 
at room temperature before the enzyme reaction. The 
gel was incubated overnight at 37°C in enzyme buffer 
containing 50  mmol/L Tris, pH 7.5, 200  mmol/L NaCl, 
5 mmol/L CaCl2, and 0.02% Brij-35. Area of gelatin deg-
radation, identified as MMP activity, appeared as dis-
tinct white band after staining the gel with simply blue 
(Invitrogen, Germany). The intensities of both pro- and 
active MMP-9 were documented by a digital gel-imaging 
system (Thermo Scientific) and bands were analyzed by 
densitometry using imageJ.
Enzyme activity
CTSK activity was measured using a CTSK activity 
assay kit (Biovision Research Products, Germany). The 
fluorescence-based assay uses a preferred CTSK sub-
strate sequence labeled with amino-4-trifluoromethyl 
Coumarin. The substrate was incubated with whole tis-
sue lysate or CM in reaction buffer at 37°C for 1 h. The 
specificity of the assay was confirmed by incubating 
samples in the presence of cathepsin-specific inhibitors 
(K141-100-4-BV, Biovision Research Products, Ger-
many) [37]. The fluorescence was measured with 400-
nm excitation filter and 528-nm emission filter. MMP-9 
activity was measured using the fluorescence substrate 
Mca-RPPGFSAFK(Dnp) (Enzo Life sciences, Germany). 
CM or rhMMP-9 was incubated with PBS with Mg2+ and 
Ca2+ for 4  h and fluorescence was measured with 320-
nm excitation filter and 400-nm emission filter. MMP-3 
activity was measured using a MMP-3 activity assay kit 
(K783-100-BV, Biovision Research Products, Germany) 
according to manufactures instructions. The fluores-
cence was measured with 320-nm excitation filter and 
400-nm emission filter. rhCTSK (BML-SE553-0010) and 
rhproMMP-9 (ALX-200-430-C010) was purchased from 
Enzo Life Sciences and MMP-3 was obtained from Life 
Technologies (10467-HNAE-5).
Statistics
Data are shown as mean  ±  SD. Statistical analysis was 
done using GraphPad Prism software. A 2 tailed Stu-
dent’s t test were used for all comparisons. P < 0.05 was 
considered significant.
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